GlobeNewswire by notified

Ageas reports first half-year results 2022


Ageasreportsfirst half-yearresults 2022

  • The strong commercial start continued across the business
  • Excelling on all operating targets
  • Interim dividend of EUR 1.5 per share

  • Groupnetresult excluding RPN(i) amounted to EUR456million
  • Group inflows were up 5% to EUR 9 billion with increases in both Life and Non-Life
  • Life inflows increased by 5% to EUR 6.3 billion driven by Belgium and new business in China
  • Non-Life inflows were up 5% to EUR 2.7 billion mainly thanks to Belgium and Portugal
  • Combined ratio stood at 94.9%, including 5pp impact from adverse weather events in Belgium and the UK during the first quarter
  • Operating Margin Guaranteed stood at 95 bps and Operating Margin Unit-Linked amounted to 39 bps
  • Shareholders’ equity amounted to EUR 9 billion or EUR 49.11 per share
  • Group Solvency IIageas ratio improved to 221%, well within the Group’s risk appetite
  • The Operational Capital Generation and the Operational Free Capital Generation respectively amounted to EUR 844 million and 569 million EUR, illustrating the strong performance of the Group
  • General Account Total Liquid Assets as at 30 June 2022 stood at EUR 1.2 billion
  • Life Technical Liabilities excl. shadow accounting of the consolidated entities were down 3% compared to end 2021 to EUR 73 billion

Acompleteoverviewofthefiguresandcomparisonwithpreviousyearcanbefoundonpage5ofthispressreleaseandontheAgeaswebsite.Key figures and main highlights on the segments can be found in theAnnexes of this press release.

Impact24 -- Non-financialandSustainabilityAchievements
  • AG in Belgium has maintained its ‘Towards Sustainability Label’, making AG the biggest provider of Sustainable Financial Insurances in Belgium. Also at AG, all Life insurance products now meet the requirements of Article 8 of the SFDR Regulation.
  • In the UK, Ageas was recognised as Personal Lines Insurer of the Year for the second consecutive year at the independently judged British Insurance Awards.

Hans De Cuyper, CEO Ageas:
“ I am very pleased that we are building further on the positive start we made at the beginning of this year with an exceptionally strong second quarter. Both operationally and commercially, we performed very well across regions and product lines. Also notable is the post-covid sales momentum in most Asian countries.
Thanks to the solid underlying performance in both Europe and the non-controlled partnerships in Asia, reflected in improving Life margins and a strong combined ratio, we feel confident in confirming the outlook of EUR 1 billion net profit for 2022.
Our strong capital position and free capital generation allows us to strengthen the growth commitment we made for our dividend under Impact 24, and consequently we are happy to announce today an interim dividend of EUR 1.5 per share for our shareholders.
Ageas continues to perform well in terms of its core business, and at the same time it is taking important steps in living up to its non-financial commitments under Impact24 in the field of sustainability, climate and health and wellbeing. “


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Clean Motion AB skriver under projektavtal med EU8.12.2023 19:09:01 CET | Pressemelding

Elfordonstillverkaren Clean Motion AB har skrivit under ett projektavtal inom EU Horizon Europe programmet. Projektet GIANTS (Green Intelligent Affordable Nano Transport Solutions) har totalt 23 projektpartners och en total budget på 15,1 miljoner Euro varav 12 miljoner Euro är bidrag från EU. Clean Motion har den tredje största budgeten och kommer att tilldelas ett bidrag från EU på 1,3 miljoner Euro fördelat över projektperioden på 42 månader, med start i januari 2024. Clean Motion AB, en ledare inom utvecklingen av hållbara transportlösningar, är stolta över att meddela sitt deltagande i GIANTS-projektet, finansierat av EU inom ramen för Horizon Europe-programmet. Projektets totala budget uppgår till 15,1 miljoner euro där EU står för 12 miljoner euro. Clean Motions totala budget i projektet är 1,9 miljoner euro med EU-finansiering om 1,3 miljoner euro. Inom projektet som löper från januari 2024 och 42 månader framåt kommer vi att samarbeta med 22 andra partners, bland andra Renault

Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release

PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;

Innofactor Plc: Share Repurchase 8.12.20238.12.2023 17:30:00 CET | Press release

Innofactor Plc Announcement 8.12.2023Innofactor Plc: Share Repurchase 8.12.2023In the Helsinki Stock ExchangeTrade date 8.12.2023Bourse trade BuyShare IFA1VAmount 4,400SharesAverage price/ share 1.1700EURTotal cost 5,148.00EURInnofactor Plc now holds a total of 580 029 sharesincluding the shares repurchased on 8.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 Attachment Innofactor_8.12_trades